Prescient Therapeutics (ASX: PTX)
Live Investor Briefing
Tuesday, 5th July 12pm (AEST)
Please join a special investor briefing with Prescient Therapeutics CEO and MD Steven Yatomi-Clarke.
In the session, Steven will discuss:
- Why Prescient is positioned at the forefront of a current revolution within oncology, the largest sector in healthcare at US$280 billion.
- How Prescient’s OmniCAR and CellPryme platforms can potentially enable and enhance cancer therapies as it moves from ‘treatment’ towards ‘personalised cure’.
- How the company can address an ecosystem of many potential partners leading togreater upside and revenue opportunities and diversified commercial risk.
- The ongoing progress of its targeted therapies, PTX-100 and PTX-200, through clinical studies and towards commercialisation.
This is a live and interactive online session, and participants are encouraged to ask questions. Joining only requires an internet connection. Spots are limited, so secure yours today.
Book Your Spot
By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach Markets have been engaged to help manage our investor communications.
FEATURED SPEAKER
Steven Yatomi Clarke
CEO and Managing Director
Steven took over as CEO of Prescient Therapeutics in 2016 and has overseen its progression from start-up phase. Steven manages a team in Australia and the US and has been instrumental in strategy development; licensing; initiating and managing clinical trials; fundraising and business development. He has been a collaborator on various immunotherapy research projects.